The Benefits From Giving Makers of Conventional 'Small Molecule' Drugs Longer Exclusivity Over Clinical Trial Data

Health Affairs - United States
doi 10.1377/hlthaff.2009.1056
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Health Affairs (Project Hope)

Related search

The Benefits of in Silico Modeling to Identify Possible Small-Molecule Drugs and Their Off-Target Interactions

Future Medicinal Chemistry
Drug DiscoveryMolecular MedicinePharmacology
2018English

Nonclinical Evaluations of Small-Molecule Oncology Drugs: Integration Into Clinical Dose Optimization and Toxicity Management

Clinical Cancer Research
Cancer ResearchOncology
2016English

Binding of Small Molecule Drugs to Porcine Vitreous Humor

Molecular Pharmaceutics
Drug DiscoveryMolecular MedicinePharmaceutical Science
2018English

Randomized Clinical Trial of Endovenous Laser Ablation Versus Conventional Surgery for Small Saphenous Varicose Veins

Journal of Vascular Surgery
SurgeryCardiovascular MedicineCardiology
2013English

Economic Impact of the End of the Market Exclusivity for Orphan Drugs

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

The Benefits of Giving a Massage on the Mental State of Massage Therapists: A Randomized, Controlled Trial

Journal of Alternative and Complementary Medicine
Alternative MedicineComplementary
2012English

Intervivos Giving Over the Lifecycle

SSRN Electronic Journal
2011English

Where Do Recent Small Molecule Clinical Development Candidates Come From?

English

A Defence of the Small Clinical Trial

BMJ
1986English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy